CAPIENDA BIOTECH is selected as a top 15 entrant for the 2020 BI Innovation Prize being awarded by Boehringer Ingelheim GmbH and the Boehringer Ingelheim Venture Fund. Dr. Mark Bernard presents the business opportunity and biotechnology innovation to the SDAC on February 27, 2020. The Golden Ticket is a $75,000 value for BioLabs shared laboratory space in San Diego for one year.
CAPIENDA BIOTECH advances to the Quarterfinals of the San Diego Angel Conference. Dr. Mark Bernard will present the business opportunity and biotechnology innovation to the SDAC on February 5, 2020. Competition is for $200,000 in funding.
CAPIENDA BIOTECH completed the National Science Foundation Innovation Corps Program at Tech Launch Arizona (TLA) and the University of Arizona. Capienda was a member of Cohort #9 at TLA.
The goal of the NSF Innovation Corps (I-Corps) Program is to reduce the time and risk associated with translating promising ideas and technologies from the laboratory to the marketplace. The I-Corps Program utilizes experiential learning of customer and industry discovery, coupled with first-hand investigation of industrial processes, to quickly assess the translational potential of inventions. The I-Corps Program is designed to support the commercialization of so-called "deep technologies,” or those revolving around fundamental discoveries in science and engineering. The I-Corps program addresses the skill and knowledge gap associated with the transformation of basic research into deep technology ventures (DTVs).